- Home
- IAG vs RYTM Comparison
IAG vs RYTM Comparison
Compare IAG & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAG
- RYTM
- Stock Information
- Founded
- IAG 1990
- RYTM 2008
- Country
- IAG Canada
- RYTM United States
- Employees
- IAG 5300
- RYTM N/A
- Industry
- IAG Precious Metals
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- IAG Basic Materials
- RYTM Health Care
- Exchange
- IAG Nasdaq
- RYTM Nasdaq
- Market Cap
- IAG 4.5B
- RYTM 3.8B
- IPO Year
- IAG 1996
- RYTM 2017
- Fundamental
- Price
- IAG $7.03
- RYTM $63.76
- Analyst Decision
- IAG Buy
- RYTM Strong Buy
- Analyst Count
- IAG 7
- RYTM 12
- Target Price
- IAG $7.77
- RYTM $74.92
- AVG Volume (30 Days)
- IAG 17.7M
- RYTM 998.0K
- Earning Date
- IAG 05-06-2025
- RYTM 05-07-2025
- Dividend Yield
- IAG N/A
- RYTM N/A
- EPS Growth
- IAG 677.20
- RYTM N/A
- EPS
- IAG 1.50
- RYTM N/A
- Revenue
- IAG $1,633,000,000.00
- RYTM $130,126,000.00
- Revenue This Year
- IAG $38.27
- RYTM $43.84
- Revenue Next Year
- IAG $6.29
- RYTM $65.62
- P/E Ratio
- IAG $4.69
- RYTM N/A
- Revenue Growth
- IAG 65.43
- RYTM 68.06
- 52 Week Low
- IAG $3.44
- RYTM $35.17
- 52 Week High
- IAG $8.38
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- IAG 53.90
- RYTM 63.66
- Support Level
- IAG $7.06
- RYTM $59.03
- Resistance Level
- IAG $7.47
- RYTM $62.85
- Average True Range (ATR)
- IAG 0.43
- RYTM 4.27
- MACD
- IAG -0.00
- RYTM 0.51
- Stochastic Oscillator
- IAG 55.45
- RYTM 98.78
About IAG Iamgold Corporation
Iamgold Corp is a mid-tier gold mining company. The company operating gold mines are divided into geographic segments such as Cote Gold mine - Canada, Burkina Faso - Essakane mine, Westwood mine - Canada. The company's s non-gold mine segments are Exploration and evaluation and development, and Corporate - which includes royalty interests. The company generates the majority of its revenue from the Cote Gold mine segment.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.